Anirban Maitra, Director of the Perlmutter Cancer Center, shared a post on X:
“New Nature Communications study by Dr. Neeha Zaidi, reiterating what has also been shown with mRNA and amphiphilic peptide vaccines – it IS possible to generate long lasting tumor antigen specific T cell responses against Pancreatic Cancer in the postoperative setting.”
Title: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
Authors: Amanda L. Huff, S. Daniel Haldar, Alexander A. Gergis, Hejia Henry Wang, Ludmila Danilova, Thatcher Heumann, Maureen Berg, Yuxuan Wang, Lalitya Andaloori, Alexei Hernandez, Gabriella Longway, Benjamin Barrett, Zirui Zhu, Emily Davis-Marcisak, Christopher Thoburn, James Leatherman, Sarah Mitchell, Jae W. Lee, Daniel H. Shu, Maximillian F. Konig, Brian J. Mog, Janelle Montagne, Erin M. Coyne, Katherine Bever, Marina Baretti, Mark Yarchoan, Robert A. Anders, Luciane T. Kagohara, Daniel Laheru, Amy M. Thomas, Jennifer Durham, Julie M. Nauroth, Jiayun Lu, Hao Wang, Elana J. Fertig, Won Jin Ho, Nilofer S. Azad, Elizabeth M. Jaffee, Neeha Zaidi
Read The Full Article
Other articles featuring KRAS on OncoDaily.